Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Oct;6(4):679–692. doi: 10.1016/j.nurt.2009.07.006

Targeting voltage-gated calcium channels for neuropathic pain management

Danielle Perret 1,2, Z David Luo 1,3,4,✉
PMCID: PMC2755636  NIHMSID: NIHMS133252  PMID: 19789072

Summary

Voltage-gated calcium channels (VGCC) play obligatory roles in diverse physiological functions. Pathological conditions leading to changes in their biophysical properties and expression levels may cause malfunctions of VGCC-mediated activities, resulting in disease states. It is believed that changes in VGCC properties under pain-inducing conditions may play a causal role in the development of chronic pain, including nerve injury-induced pain or neuropathic pain. For the past several decades, preclinical and clinical research in developing VGCC blockers or modulators for chronic pain management has been fruitful, leading to some U.S. Food and Drug Administration-approved drugs currently available for chronic pain management. However, their efficacy in pain relief is limited in some patients, and their long-term use is limited by their side-effect profiles. Certainly, there is room for improvement in developing more subtype-specific VGCC blockers or modulators for chronic pain conditions. In this review, we summarized the most recent preclinical and clinical studies related to chronic pain medications acting on the VGCC. We also included clinical trials aiming to expand the application of approved VGCC drugs to different pain states derived from various pathological conditions, as well as drug combination therapies trying to improve the efficacies and side-effect profiles of current pain medications.

Key Words: Chronic, neuropathic pain, voltage-gated calcium channels, analgesics

References

  • 1.Mitka M. “Virtual textbook” on pain developed: effort seeks to remedy gap in medical education. JAMA. 2003;290:2395–2395. doi: 10.1001/jama.290.18.2395. [DOI] [PubMed] [Google Scholar]
  • 2.Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16:521–555. doi: 10.1146/annurev.cellbio.16.1.521. [DOI] [PubMed] [Google Scholar]
  • 3.Dolphin AC. Beta subunits of voltage-gated calcium channels. J Bioenerg Biomembr. 2003;35:599–620. doi: 10.1023/b:jobb.0000008026.37790.5a. [DOI] [PubMed] [Google Scholar]
  • 4.Dolphin AC. Beta subunits of voltage-gated calcium channels. J Bioenerg Biomembr. 2003;35:599–620. doi: 10.1023/b:jobb.0000008026.37790.5a. [DOI] [PubMed] [Google Scholar]
  • 5.Klugbauer N, Lacinova L, Marais E, Hobom M, Hofmann F. Molecular diversity of the calcium channel a2d subunit. J Neurosci. 1999;19:684–691. doi: 10.1523/JNEUROSCI.19-02-00684.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Qin N, Yagel S, Momplaisir ML, Codd EE, D’Andrea MR. Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. Mol Pharmacol. 2002;62:485–496. doi: 10.1124/mol.62.3.485. [DOI] [PubMed] [Google Scholar]
  • 7.Marais E, Klugbauer N, Hofmann F. Calcium channel alpha2delta subunits-structure and gabapentin binding. Mol Pharmacol. 2001;59:1243–1248. doi: 10.1124/mol.59.5.1243. [DOI] [PubMed] [Google Scholar]
  • 8.Kim HL, Kim H, Lee P, King RG, Chin H. Rat brain expresses an alternatively spliced form of the dihydropyridine-sensitive L-type calcium channel alpha 2 subunit. Proc Natl Acad Sci U S A. 1992;89:3251–3255. doi: 10.1073/pnas.89.8.3251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Angelotti T, Hofmann F. Tissue-specific expression of splice variants of the mouse voltage-gated calcium channel alpha2/delta subunit. Febs Letters. 1996;397:331–337. doi: 10.1016/s0014-5793(96)01205-7. [DOI] [PubMed] [Google Scholar]
  • 10.Ellis SB, Williams ME, Ways NR, et al. Sequence and expression of mRNAs encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel. Science. 1988;241:1661–1664. doi: 10.1126/science.2458626. [DOI] [PubMed] [Google Scholar]
  • 11.De Jongh KS, Warner C, Catterall WA. Subunits of purified calcium channels. Alpha 2 and delta are encoded by the same gene. J Biol Chem. 1990;265:14738–14741. [PubMed] [Google Scholar]
  • 12.Brickley K, Campbell V, Berrow N, et al. Use of site-directed antibodies to probe the topography of the alpha 2 subunit of voltage-gated Ca2+ channels. Febs Letters. 1995;364:129–133. doi: 10.1016/0014-5793(95)00371-f. [DOI] [PubMed] [Google Scholar]
  • 13.Gurnett CA, De Waard M, Campbell KP. Dual function of the voltage-dependent Ca2+ channel alpha 2 delta subunit in current stimulation and subunit interaction. Neuron. 1996;16:431–440. doi: 10.1016/s0896-6273(00)80061-6. [DOI] [PubMed] [Google Scholar]
  • 14.Wiser O, Trus M, Tobi D, Halevi S, Giladi E, Atlas D. The alpha 2/delta subunit of voltage sensitive Ca2+ channels is a single transmembrane extracellular protein which is involved in regulated secretion. Febs Letters. 1996;379:15–20. doi: 10.1016/0014-5793(95)01475-6. [DOI] [PubMed] [Google Scholar]
  • 15.Mikami A, Imoto K, Tanabe T, et al. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature. 1989;340:230–233. doi: 10.1038/340230a0. [DOI] [PubMed] [Google Scholar]
  • 16.Mori Y, Friedrich T, Kim MS, et al. Primary structure and functional expression from complementary DNA of a brain calcium channel. Nature. 1991;350:398–402. doi: 10.1038/350398a0. [DOI] [PubMed] [Google Scholar]
  • 17.Hullin R, Singer-Lahat D, Freichel M, et al. Calcium channel beta subunit heterogeneity: functional expression of cloned cDNA from heart, aorta and brain. Embo J. 1992;11:885–890. doi: 10.1002/j.1460-2075.1992.tb05126.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Williams ME, Feldman DH, McCue AF, et al. Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype. Neuron. 1992;8:71–84. doi: 10.1016/0896-6273(92)90109-q. [DOI] [PubMed] [Google Scholar]
  • 19.Brust PF, Simerson S, McCue AF, et al. Human neuronal voltage-dependent calcium channels: studies on subunit structure and role in channel assembly. Neuropharmacology. 1993;32:1089–1102. doi: 10.1016/0028-3908(93)90004-m. [DOI] [PubMed] [Google Scholar]
  • 20.Kang MG, Felix R, Campbell KP. Long-term regulation of voltage-gated Ca(2+) channels by gabapentin. FEBS Lett. 2002;528:177–182. doi: 10.1016/s0014-5793(02)03295-7. [DOI] [PubMed] [Google Scholar]
  • 21.Gurnett CA, Felix R, Campbell KP. Extracellular interaction of the voltage-dependent Ca2+ channel alpha2delta and alphal sub-units. J Biol Chem. 1997;272:18508–18512. doi: 10.1074/jbc.272.29.18508. [DOI] [PubMed] [Google Scholar]
  • 22.Wolf M, Eberhart A, Glossmann H, Striessnig J, Grigorieff N. Visualization of the domain structure of an L-type Ca2+ channel using electron cryo-microscopy. J Mol Biol. 2003;332:171–182. doi: 10.1016/s0022-2836(03)00899-4. [DOI] [PubMed] [Google Scholar]
  • 23.Bauer CS, Simerson S, McCue AF, et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci. 2009;29:4076–4088. doi: 10.1523/JNEUROSCI.0356-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A. 2008;105:3628–3633. doi: 10.1073/pnas.0708930105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Takahashi M, Seagar MJ, Jones JF, Reber BF, Catterall WA. Subunit structure of dihydropyridine-sensitive calcium channels from skeletal muscle. Proc Natl Acad Sci U S A. 1987;84:5478–5482. doi: 10.1073/pnas.84.15.5478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Catterall WA. Structure and function of voltage-sensitive ion channels. Science. 1988;242:50–61. doi: 10.1126/science.2459775. [DOI] [PubMed] [Google Scholar]
  • 27.Catterall WA. Functional subunit structure of voltage-gated calcium channels. Science. 1991;253:1499–1500. doi: 10.1126/science.1654596. [DOI] [PubMed] [Google Scholar]
  • 28.Black JL, Lennon VA. Identification and cloning of putative human neuronal voltage-gated calcium channel gamma-2 and gamma-3 subunits: neurologic implications. Mayo Clin Proc. 1999;74:357–361. doi: 10.4065/74.4.357. [DOI] [PubMed] [Google Scholar]
  • 29.Kang MG, Chen CC, Felix R, et al. Biochemical and biophysical evidence for gamma 2 subunit association with neuronal voltage-activated Ca2+ channels. J Biol Chem. 2001;276:32917–32924. doi: 10.1074/jbc.M100787200. [DOI] [PubMed] [Google Scholar]
  • 30.Klugbauer N, Dai S, Specht V, et al. A family of gamma-like calcium channel subunits. FEBS Lett. 2000;470:189–197. doi: 10.1016/s0014-5793(00)01306-5. [DOI] [PubMed] [Google Scholar]
  • 31.Letts VA, Felix R, Biddlecome GH, et al. The mouse stargazer gene encodes a neuronal Ca2+-channel gamma subunit. Nat Genet. 1998;19:340–347. doi: 10.1038/1228. [DOI] [PubMed] [Google Scholar]
  • 32.Moss FJ, Viard P, Davies A, et al. The novel product of a five-exon stargazin-related gene abolishes Ca(V)2.2 calcium channel expression. Embo J. 2002;21:1514–1523. doi: 10.1093/emboj/21.7.1514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Eitel EA, Campbell KP, Harpold MM, et al. Nomenclature of voltage-gated calcium channels. Neuron. 2000;25:533–535. doi: 10.1016/s0896-6273(00)81057-0. [DOI] [PubMed] [Google Scholar]
  • 34.Jan LY, Jan YN. Voltage-sensitive ion channels. Cell. 1989;56:13–25. doi: 10.1016/0092-8674(89)90979-3. [DOI] [PubMed] [Google Scholar]
  • 35.Spedding M, Lepagnol J. Pharmacology of sodium and calcium channel modulation in neurons: implications for neuroprotection. Biochem Soc Trans. 1995;23:633–636. doi: 10.1042/bst0230633. [DOI] [PubMed] [Google Scholar]
  • 36.Tsien RW, Ellinor PT, Horne WA. Molecular diversity of voltage-dependent Ca2+ channels. Trends Pharmacol Sci. 1991;12:349–354. doi: 10.1016/0165-6147(91)90595-j. [DOI] [PubMed] [Google Scholar]
  • 37.Finkbeiner S, Greenberg ME. Ca2+ channel-regulated neuronal gene expression. J Neurobiol. 1998;37:171–189. [PubMed] [Google Scholar]
  • 38.Belardetti F, Zamponi GW. Linking calcium-channel isoforms to potential therapies. Curr Opin Investig Drugs. 2008;9:707–715. [PubMed] [Google Scholar]
  • 39.Davies JN, Zamponi GW. Old proteins, developing roles: the regulation of calcium channels by synaptic proteins. Channels (Austin) 2008;2:130–138. doi: 10.4161/chan.2.2.6214. [DOI] [PubMed] [Google Scholar]
  • 40.Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev. 2009;60:84–89. doi: 10.1016/j.brainresrev.2008.12.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D. Inherited neuronal ion channelopathies: new windows on complex neurological diseases. J Neurosci. 2008;28:11768–11777. doi: 10.1523/JNEUROSCI.3901-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Yaksh TL. Calcium channels as therapeutic targets in neuropathic pain. J Pain. 2006;7:S13–30. doi: 10.1016/j.jpain.2005.09.007. [DOI] [PubMed] [Google Scholar]
  • 43.McGivem JG, McDonough SI. Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord. 2004;3:457–478. doi: 10.2174/1568007043336743. [DOI] [PubMed] [Google Scholar]
  • 44.Bourinet E, Zamponi GW. Voltage gated calcium channels as targets for analgesics. Curr Top Med Chem. 2005;5:539–546. doi: 10.2174/1568026054367610. [DOI] [PubMed] [Google Scholar]
  • 45.Schroeder CI, Doering CJ, Zamponi GW, Lewis RJ. N-type calcium channel blockers: novel therapeutics for the treatment of pain. Med Chem. 2006;2:535–543. doi: 10.2174/157340606778250216. [DOI] [PubMed] [Google Scholar]
  • 46.Kisilevsky AE, Zamponi GW. Presynaptic calcium channels: structure, regulators, and blockers. Handb Exp Pharmacol 2008: 45–75. [DOI] [PubMed]
  • 47.Catterall WA, Few AP. Calcium channel regulation and presynaptic plasticity. Neuron. 2008;59:882–901. doi: 10.1016/j.neuron.2008.09.005. [DOI] [PubMed] [Google Scholar]
  • 48.Fuchs A, Rigaud M, Sarantopoulos CD, Filip P, Hogan QH. Contribution of calcium channel subtypes to the intracellular calcium signal in sensory neurons: the effect of injury. Anesthesiology. 2007;107:117–127. doi: 10.1097/01.anes.0000267511.21864.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Diaz A, Dickenson AH. Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation. Pain. 1997;69:93–100. doi: 10.1016/s0304-3959(96)03271-x. [DOI] [PubMed] [Google Scholar]
  • 50.Matthews EA, Dickenson AH. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain. 2001;92:235–246. doi: 10.1016/s0304-3959(01)00255-x. [DOI] [PubMed] [Google Scholar]
  • 51.Matthews EA, Dickenson AH. Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001;415:141–149. doi: 10.1016/s0014-2999(01)00812-3. [DOI] [PubMed] [Google Scholar]
  • 52.Vanegas H, Schaible H. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain. 2000;85:9–18. doi: 10.1016/s0304-3959(99)00241-9. [DOI] [PubMed] [Google Scholar]
  • 53.Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron. 1992;9:1099–1115. doi: 10.1016/0896-6273(92)90069-p. [DOI] [PubMed] [Google Scholar]
  • 54.Kerr LM, Filloux F, Olivera BM, Jackson H, Wamsley JK. Autoradiographic localization of calcium channels with [125I]omega-conotoxin in rat brain. Eur J Pharmacol. 1988;146:181–183. doi: 10.1016/0014-2999(88)90501-8. [DOI] [PubMed] [Google Scholar]
  • 55.Gohil K, Bell JR, Ramachandran J, Miljanich GP. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC) Brain Res. 1994;653:258–266. doi: 10.1016/0006-8993(94)90398-0. [DOI] [PubMed] [Google Scholar]
  • 56.Pertovaara A. Noradrenergic pain modulation. Prog Neurobiol. 2006;80:53–83. doi: 10.1016/j.pneurobio.2006.08.001. [DOI] [PubMed] [Google Scholar]
  • 57.Bourinet E, Soong TW, Stea A, Snutch TP. Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. Proc Natl Acad Sci U S A. 1996;93:1486–1491. doi: 10.1073/pnas.93.4.1486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Altier C, Zamponi GW. Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci. 2004;25:465–470. doi: 10.1016/j.tips.2004.07.004. [DOI] [PubMed] [Google Scholar]
  • 59.Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther. 1994;269:1117–1123. [PubMed] [Google Scholar]
  • 60.Maggi CA, Tramontana M, Cecconi R, Santicioli P. Neurochemical evidence for the involvement of N-type calcium channels in transmitter secretion from peripheral endings of sensory nerves in guinea pigs. Neurosci Lett. 1990;114:203–206. doi: 10.1016/0304-3940(90)90072-h. [DOI] [PubMed] [Google Scholar]
  • 61.Santicioli P, Del Bianco E, Tramontana M, Geppetti P, Maggi CA. Release of calcitonin gene-related peptide like-immunoreactivity induced by electrical field stimulation from rat spinal afferents is mediated by conotoxin-sensitive calcium channels. Neurosci Lett. 1992;136:161–164. doi: 10.1016/0304-3940(92)90039-a. [DOI] [PubMed] [Google Scholar]
  • 62.Evans AR, Nicol GD, Vasko MR. Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons. Brain Res. 1996;712:265–273. doi: 10.1016/0006-8993(95)01447-0. [DOI] [PubMed] [Google Scholar]
  • 63.Saegusa H, Kurihara T, Zong S, et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. Embo J. 2001;20:2349–2356. doi: 10.1093/emboj/20.10.2349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Saegusa H, Matsuda Y, Tanabe T. Effects of ablation of N- and R-type Ca(2+) channels on pain transmission. Neurosci Res. 2002;43:1–7. doi: 10.1016/s0168-0102(02)00017-2. [DOI] [PubMed] [Google Scholar]
  • 65.Hatakeyama S, Wakamori M, Ino M, et al. Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels. Neuroreport. 2001;12:2423–2427. doi: 10.1097/00001756-200108080-00027. [DOI] [PubMed] [Google Scholar]
  • 66.Bell TJ, Thaler C, Castiglioni AJ, Helton TD, Lipscombe D. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron. 2004;41:127–138. doi: 10.1016/s0896-6273(03)00801-8. [DOI] [PubMed] [Google Scholar]
  • 67.Lin Y, McDonough SI, Lipscombe D. Alternative Splicing in the voltage-sensing region of N-type CaV2.2 channels modulates channel kinetics. J Neurophysiol. 2004;92:2820–2830. doi: 10.1152/jn.00048.2004. [DOI] [PubMed] [Google Scholar]
  • 68.Lin Z, Haus S, Edgerton J, Lipscombe D. Identification of functionally distinct isoforms of the N-type Ca2+ channel in rat sympathetic ganglia and brain. Neuron. 1997;18:153–166. doi: 10.1016/s0896-6273(01)80054-4. [DOI] [PubMed] [Google Scholar]
  • 69.Miljanich GP. In: Venoms to drugs. Heron Island, Australia. 2005. Available at: http://www.venomstodrugs.com/index.html? page=107301&pid=0.
  • 70.Hillyard DR, Monje VD, Mintz IM, et al. A new Conus peptide ligand for mammalian presynaptic Ca2+ channels. Neuron. 1992;9:69–77. doi: 10.1016/0896-6273(92)90221-x. [DOI] [PubMed] [Google Scholar]
  • 71.Lewis RJ, Nielsen KJ, Craik DJ, et al. Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem. 2000;275:35335–35344. doi: 10.1074/jbc.M002252200. [DOI] [PubMed] [Google Scholar]
  • 72.Nadasdi L, Yamashiro D, Chung D, Tarczy-Homoch K, Adriaenssens P, Ramachandran J. Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels. Biochemistry. 1995;34:8076–8081. doi: 10.1021/bi00025a013. [DOI] [PubMed] [Google Scholar]
  • 73.Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain. 2002;96:119–127. doi: 10.1016/s0304-3959(01)00436-5. [DOI] [PubMed] [Google Scholar]
  • 74.Wang YX, Gao D, Pettus M, Phillips C, Bowersox SS. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain. 2000;84:271–281. doi: 10.1016/s0304-3959(99)00214-6. [DOI] [PubMed] [Google Scholar]
  • 75.Wang YX, Pettus M, Gao D, Phillips C, Scott Bowersox S. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain. 2000;84:151–158. doi: 10.1016/s0304-3959(99)00197-9. [DOI] [PubMed] [Google Scholar]
  • 76.Sluka KA. Blockade of N- and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. J Pharmacol Exp Ther. 1998;287:232–237. [PubMed] [Google Scholar]
  • 77.Lynch SS, Cheng CM, Yee JL. Intrathecal ziconotide for refractory chronic pain. Ann Pharmacother. 2006;40:1293–1300. doi: 10.1345/aph.1G584. [DOI] [PubMed] [Google Scholar]
  • 78.Klotz U. Ziconotide—a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain—a short review. Int J Clin Pharmacol Ther. 2006;44:478–483. doi: 10.5414/cpp44478. [DOI] [PubMed] [Google Scholar]
  • 79.Wermeling DP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy. 2005;25:1084–1094. doi: 10.1592/phco.2005.25.8.1084. [DOI] [PubMed] [Google Scholar]
  • 80.Atanassoff PG, Hartmannsgruber MW, Thrasher J, et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med. 2000;25:274–278. doi: 10.1016/s1098-7339(00)90010-5. [DOI] [PubMed] [Google Scholar]
  • 81.Mathur VS. Ziconotide: a new pharmacological class of drug for the management of pain. Sem Anesth Periop Med Pain. 2000;19:67–75. [Google Scholar]
  • 82.Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63–70. doi: 10.1001/jama.291.1.63. [DOI] [PubMed] [Google Scholar]
  • 83.Wallace MS, Charapata SG, Fisher R, et al. Intrathecal Ziconotide in the treatment of chronic non-malignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9:75–86. doi: 10.1111/j.1525-1403.2006.00055.x. [DOI] [PubMed] [Google Scholar]
  • 84.Lyseng-Williamson KA, Perry C. Ziconotide. CNS Drugs. 2006;20:331–341. doi: 10.2165/00023210-200620040-00007. [DOI] [PubMed] [Google Scholar]
  • 85.Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393–406. doi: 10.1016/j.jpainsymman.2005.10.003. [DOI] [PubMed] [Google Scholar]
  • 86.Fisher R, Hassenbusch S, Krames E, et al. A consensus statement regarding the present suggested titration for priait (ziconotide) Neuromodulation. 2005;8:153–154. doi: 10.1111/j.1525-1403.2005.05232.x. [DOI] [PubMed] [Google Scholar]
  • 87.Saulino M. Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report. Spinal Cord. 2007;45:749–752. doi: 10.1038/sj.sc.3102027. [DOI] [PubMed] [Google Scholar]
  • 88.Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63–70. doi: 10.1001/jama.291.1.63. [DOI] [PubMed] [Google Scholar]
  • 89.Snutch TP. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx. 2005;2:662–670. doi: 10.1602/neurorx.2.4.662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Wermeling DP, Berger JR. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Pharmacotherapy. 2006;26:395–402. doi: 10.1592/phco.26.3.395. [DOI] [PubMed] [Google Scholar]
  • 91.Yarotskyy V, Elmslie KS. Omega-conotoxin GVIA alters gating charge movement of N-type (CaV2.2) calcium channels. J Neurophysiol. 2009;101:332–340. doi: 10.1152/jn.91064.2008. [DOI] [PubMed] [Google Scholar]
  • 92.Thompson JC, Dunbar E, Laye RR. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician. 2006;9:147–152. [PubMed] [Google Scholar]
  • 93.Vitale V, Battelli D, Gasperoni E, Monachese N. Intrathecal therapy with ziconotide: clinical experience and considerations on its use. Minerva Anestesiol. 2008;74:727–733. [PubMed] [Google Scholar]
  • 94.Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2007;10:300–328. doi: 10.1111/j.1525-1403.2007.00128.x. [DOI] [PubMed] [Google Scholar]
  • 95.Smith HS, Deer TR, Staats PS, Singh V, Sehgal N, Cordner H. Intrathecal drug delivery. Pain Physician. 2008;11:S89–S104. [PubMed] [Google Scholar]
  • 96.Pin JP, Bockaert J. Omega-conotoxin GVIA and dihydropyridines discriminate two types of Ca2+ channels involved in GABA release from striatal neurons in culture. Eur J Pharmacol. 1990;188:81–84. doi: 10.1016/0922-4106(90)90250-2. [DOI] [PubMed] [Google Scholar]
  • 97.Zhang SP, Kauffman J, Yagel SK, Codd EE. High-throughput screening for N-type calcium channel blockers using a scintillation proximity assay. J Biomol Screen. 2006;11:672–677. doi: 10.1177/1087057106289210. [DOI] [PubMed] [Google Scholar]
  • 98.Scott DA, Wright CE, Angus JA. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol. 2002;451:279–286. doi: 10.1016/s0014-2999(02)02247-1. [DOI] [PubMed] [Google Scholar]
  • 99.Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain. 1995;60:83–90. doi: 10.1016/0304-3959(94)00094-U. [DOI] [PubMed] [Google Scholar]
  • 100.Cousins M, Goucke R, Cher L, Brooker C. A phase I clinical trial of AM336, a novel N-type calcium channel blocker. IASP Press: 10th World Congress on Pain. 2002;200:615–P249. [Google Scholar]
  • 101.Knutsen LJ, Hobbs CJ, Earnshaw CG, et al. Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007;17:662–667. doi: 10.1016/j.bmcl.2006.10.098. [DOI] [PubMed] [Google Scholar]
  • 102.Herlitze S, Garcia DE, Mackie K, Hille B, Scheuer T, Catterall WA. Modulation of Ca2+ channels by G-protein beta gamma subunits. Nature. 1996;380:258–262. doi: 10.1038/380258a0. [DOI] [PubMed] [Google Scholar]
  • 103.Pirec V, Laurito CE, Lu Y, Yeomans DC. The combined effects of N-type calcium channel blockers and morphine on A delta versus C fiber mediated nociception. Anesth Analg. 2001;92:239–243. doi: 10.1097/00000539-200101000-00046. [DOI] [PubMed] [Google Scholar]
  • 104.Martin TJ, Eisenach JC. Pharmacology of opioid and nonopioid analgesics in chronic pain states. J Pharmacol Exp Ther. 2001;299:811–817. [PubMed] [Google Scholar]
  • 105.Sharpe IA, Gehrmann J, Loughnan ML, et al. Two new classes of conopeptides inhibit the alphal-adrenoceptor and noradrenaline transporter. Nat Neurosci. 2001;4:902–907. doi: 10.1038/nn0901-902. [DOI] [PubMed] [Google Scholar]
  • 106.Paczkowski FA, Sharpe IA, Dutertre S, Lewis RJ. chi-Conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model. J Biol Chem. 2007;282:17837–17844. doi: 10.1074/jbc.M610813200. [DOI] [PubMed] [Google Scholar]
  • 107.Nelson MT, Joksovic PM, Perez-Reyes E, Todorovic SM. The endogenous redox agent L-cysteine induces T-type Ca2+ channel-dependent sensitization of a novel subpopulation of rat peripheral nociceptors. J Neurosci. 2005;25:8766–8775. doi: 10.1523/JNEUROSCI.2527-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Todorovic SM, Jevtovic-Todorovic V. The role of T-type calcium channels in peripheral and central pain processing. CNS Neurol Disord Drug Targets. 2006;5:639–653. doi: 10.2174/187152706779025490. [DOI] [PubMed] [Google Scholar]
  • 109.Sekizawa SI, French AS, Torkkeli PH. Low-voltage-activated calcium current does not regulate the firing behavior in paired mechanosensory neurons with different adaptation properties. J Neurophysiol. 2000;83:746–753. doi: 10.1152/jn.2000.83.2.746. [DOI] [PubMed] [Google Scholar]
  • 110.Jagodic MM, Pathirathna S, Nelson MT, et al. Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci. 2007;27:3305–3316. doi: 10.1523/JNEUROSCI.4866-06.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Jagodic MM, Pathirathna S, Joksovic PM, et al. Upregulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol. 2008;99:3151–3156. doi: 10.1152/jn.01031.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Dogrul A, Gardell LR, Ossipov MH, Tulunay FC, Lai J, Porreca F. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain. 2003;105:159–168. doi: 10.1016/s0304-3959(03)00177-5. [DOI] [PubMed] [Google Scholar]
  • 113.Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109:150–161. doi: 10.1016/j.pain.2004.01.029. [DOI] [PubMed] [Google Scholar]
  • 114.Todorovic SM, Meyenburg A, Jevtovic-Todorovic V. Redox modulation of peripheral T-type Ca2+ channels in vivo: alteration of nerve injury-induced thermal hyperalgesia. Pain. 2004;109:328–339. doi: 10.1016/j.pain.2004.01.026. [DOI] [PubMed] [Google Scholar]
  • 115.Todorovic SM, Meyenburg A, Jevtovic-Todorovic V. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res. 2002;951:336–340. doi: 10.1016/s0006-8993(02)03350-4. [DOI] [PubMed] [Google Scholar]
  • 116.Choi S, Na HS, Kim J, et al. Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels. Genes Brain Behav. 2007;6:425–431. doi: 10.1111/j.1601-183X.2006.00268.x. [DOI] [PubMed] [Google Scholar]
  • 117.Bourinet E, Alloui A, Monteil A, et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. Embo J. 2005;24:315–324. doi: 10.1038/sj.emboj.7600515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Shin HS, Cheong EJ, Choi S, Lee J, Na HS. T-type Ca2+ channels as therapeutic targets in the nervous system. Curr Opin Pharmacol. 2008;8:33–41. doi: 10.1016/j.coph.2007.12.003. [DOI] [PubMed] [Google Scholar]
  • 119.Todorovic SM, Jevtovic-Todorovic V, Meyenburg A, et al. Redox modulation of T-type calcium channels in rat peripheral nociceptors. Neuron. 2001;31:75–85. doi: 10.1016/s0896-6273(01)00338-5. [DOI] [PubMed] [Google Scholar]
  • 120.Todorovic SM, Jevtovic-Todorovic V. Regulation of T-type calcium channels in the peripheral pain pathway. Channels (Austin) 2007;1:238–245. doi: 10.4161/chan.4953. [DOI] [PubMed] [Google Scholar]
  • 121.Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–251. doi: 10.1016/j.pain.2007.08.033. [DOI] [PubMed] [Google Scholar]
  • 122.Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology. 2004;63:865–873. doi: 10.1212/01.wnl.0000137341.89781.14. [DOI] [PubMed] [Google Scholar]
  • 123.Thienel U, Neto W, Schwabe SK, Vijapurkar U. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand. 2004;110:221–231. doi: 10.1111/j.1600-0404.2004.00338.x. [DOI] [PubMed] [Google Scholar]
  • 124.Khoromi S, Patsalides A, Parada S, Salehi V, Meegan JM, Max MB. Topiramate in chronic lumbar radicular pain. J Pain. 2005;6:829–836. doi: 10.1016/j.jpain.2005.08.002. [DOI] [PubMed] [Google Scholar]
  • 125.Fowler JA, Shen JY, Bettinger TL. Successful use of topiramate in a patient with severe postherpetic neuralgia. Ann Pharmacother. 2009;43:139–142. doi: 10.1345/aph.1L470. [DOI] [PubMed] [Google Scholar]
  • 126.Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain. 2003;19:59–68. doi: 10.1097/00002508-200301000-00008. [DOI] [PubMed] [Google Scholar]
  • 127.Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87:543–552. doi: 10.1016/s0092-8674(00)81373-2. [DOI] [PubMed] [Google Scholar]
  • 128.Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4:386–398. doi: 10.1038/nrn1102. [DOI] [PubMed] [Google Scholar]
  • 129.Pietrobon D. Familial hemiplegic migraine. Neurotherapeutics. 2007;4:274–284. doi: 10.1016/j.nurt.2007.01.008. [DOI] [PubMed] [Google Scholar]
  • 130.Murakami M, Nakagawasai O, Suzuki T, et al. Antinociceptive effect of different types of calcium channel inhibitors and the distribution of various calcium channel alpha 1 subunits in the dorsal horn of spinal cord in mice. Brain Res. 2004;1024:122–129. doi: 10.1016/j.brainres.2004.07.066. [DOI] [PubMed] [Google Scholar]
  • 131.Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001;21:1868–1875. doi: 10.1523/JNEUROSCI.21-06-01868.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002;303:1199–1205. doi: 10.1124/jpet.102.041574. [DOI] [PubMed] [Google Scholar]
  • 133.Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-l subunit following partial sciatic nerve injury. Brain Res Mol Brain Res. 2001;95:1–8. doi: 10.1016/s0169-328x(01)00188-7. [DOI] [PubMed] [Google Scholar]
  • 134.Wang H, Sun H, Della Penna K, et al. Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases. Neuroscience. 2002;114:529–546. doi: 10.1016/s0306-4522(02)00341-x. [DOI] [PubMed] [Google Scholar]
  • 135.Valder CR, Liu JJ, Song YH, Luo ZD. Coupling gene chip analyses and rat genetic variances in identifying potential target genes that may contribute to neuropathic allodynia development. J Neurochem. 2003;87:560–573. doi: 10.1046/j.1471-4159.2003.02016.x. [DOI] [PubMed] [Google Scholar]
  • 136.Li CY, Song YH, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci. 2004;24:8494–8499. doi: 10.1523/JNEUROSCI.2982-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137.Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271:5768–5776. doi: 10.1074/jbc.271.10.5768. [DOI] [PubMed] [Google Scholar]
  • 138.Hwang JH, Yaksh TL. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Regional Anesthesia. 1997;22:249–256. doi: 10.1016/s1098-7339(06)80010-6. [DOI] [PubMed] [Google Scholar]
  • 139.Abdi S, Lee DH, Chung JM. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg. 1998;87:1360–1366. [PubMed] [Google Scholar]
  • 140.Field MJ, McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain. 1999;80:391–398. doi: 10.1016/s0304-3959(98)00239-5. [DOI] [PubMed] [Google Scholar]
  • 141.Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831–1836. doi: 10.1001/jama.280.21.1831. [DOI] [PubMed] [Google Scholar]
  • 142.Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996;12:56–58. doi: 10.1097/00002508-199603000-00010. [DOI] [PubMed] [Google Scholar]
  • 143.Rosenberg JM, Harrell C, Ristic H, Werner RA, de Rosayro AM. The effect of gabapentin on neuropathic pain. Clin J Pain. 1997;13:251–255. doi: 10.1097/00002508-199709000-00011. [DOI] [PubMed] [Google Scholar]
  • 144.Nudler S, Piriz J, Urbano FJ, Rosato-Siri MD, Renteria ES, Uchitel OD. Ca2+ channels and synaptic transmission at the adult, neonatal, and P/Q-type deficient neuromuscular junction. Ann N Y Acad Sci. 2003;998:11–17. doi: 10.1196/annals.1254.003. [DOI] [PubMed] [Google Scholar]
  • 145.Perrier JF, Alaburda A, Hounsgaard J. Spinal plasticity mediated by postsynaptic L-type Ca2+ channels. Brain Res Brain Res Rev. 2002;40:223–229. doi: 10.1016/s0165-0173(02)00204-7. [DOI] [PubMed] [Google Scholar]
  • 146.Westenbroek RE, Hoskins L, Catterall WA. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci. 1998;18:6319–6330. doi: 10.1523/JNEUROSCI.18-16-06319.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147.Kato A, Ohkubo T, Kitamura K. Algogen-specific pain processing in mouse spinal cord: differential involvement of voltage-dependent Ca(2+) channels in synaptic transmission. Br J Pharmacol. 2002;135:1336–1342. doi: 10.1038/sj.bjp.0704578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.Reid CA, Bekkers JM, Clements JD. Presynaptic Ca2+ channels: a functional patchwork. Trends Neurosci. 2003;26:683–687. doi: 10.1016/j.tins.2003.10.003. [DOI] [PubMed] [Google Scholar]
  • 149.Talley EM, Cribbs LL, Lee JH, Daud A, Perez-Reyes E, Bayliss DA. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J Neurosci. 1999;19:1895–1911. doi: 10.1523/JNEUROSCI.19-06-01895.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150.Lambert RC, McKenna F, Maulet Y, et al. Low-voltage-activated Ca2+ currents are generated by members of the CavT subunit family (alpha1G/H) in rat primary sensory neurons. J Neurosci. 1998;18:8605–8613. doi: 10.1523/JNEUROSCI.18-21-08605.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 151.McCallum JB, Kwok WM, Mynlieff M, Bosnjak ZJ, Hogan QH. Loss of T-type calcium current in sensory neurons of rats with neuropathic pain. Anesthesiology. 2003;98:209–216. doi: 10.1097/00000542-200301000-00032. [DOI] [PubMed] [Google Scholar]
  • 152.Boroujerdi A, Kim HK, Lyu YS, et al. Injury discharges regulate calcium channel alpha-2-delta-1 subunit upregulation in the dorsal horn that contributes to initiation of neuropathic pain. Pain 2008. [DOI] [PMC free article] [PubMed]
  • 153.Zareba G. New treatment options in the management of fibromyalgia: role of pregabalin. Neuropsychiatr Dis Treat. 2008;4:1193–1201. doi: 10.2147/ndt.s3257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154.Stahl SM. Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J Clin Psychiatry. 2004;65:596–597. doi: 10.4088/jcp.v65n0501. [DOI] [PubMed] [Google Scholar]
  • 155.Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837–1842. doi: 10.1001/jama.280.21.1837. [DOI] [PubMed] [Google Scholar]
  • 156.Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94:215–224. doi: 10.1016/S0304-3959(01)00407-9. [DOI] [PubMed] [Google Scholar]
  • 157.Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia. 1994;35:795–801. doi: 10.1111/j.1528-1157.1994.tb02513.x. [DOI] [PubMed] [Google Scholar]
  • 158.Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59:1573–1579. doi: 10.1212/wnl.59.10.1573. [DOI] [PubMed] [Google Scholar]
  • 159.Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998;155:992–993. doi: 10.1176/ajp.155.7.992. [DOI] [PubMed] [Google Scholar]
  • 160.Bockbrader H. Clinical pharmacokinetics of gabapentin. Drugs Today. 1995;31:613–619. [Google Scholar]
  • 161.McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44:S17–22. [PubMed] [Google Scholar]
  • 162.Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10:276–281. doi: 10.1023/a:1018951214146. [DOI] [PubMed] [Google Scholar]
  • 163.Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand. 2000;101:359–371. doi: 10.1034/j.1600-0404.2000.0006a.x. [DOI] [PubMed] [Google Scholar]
  • 164.Hemstreet B, Lapointe M. Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther. 2001;23:520–531. doi: 10.1016/s0149-2918(01)80058-8. [DOI] [PubMed] [Google Scholar]
  • 165.Todorov AA, Kolchev CB, Todorov AB. Tiagabine and gabapentin for the management of chronic pain. Clin J Pain. 2005;21:358–361. doi: 10.1097/01.ajp.0000110637.14355.77. [DOI] [PubMed] [Google Scholar]
  • 166.Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56:1336–1344. doi: 10.1002/art.22457. [DOI] [PubMed] [Google Scholar]
  • 167.Matthews EA, Dickenson AH. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology. 2002;96:633–640. doi: 10.1097/00000542-200203000-00020. [DOI] [PubMed] [Google Scholar]
  • 168.Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–1334. doi: 10.1056/NEJMoa042580. [DOI] [PubMed] [Google Scholar]
  • 169.Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008;12:804–813. doi: 10.1016/j.ejpain.2007.12.010. [DOI] [PubMed] [Google Scholar]
  • 170.Gu R, Gusler GM, Hou SYE, et al. Extended release and dose-proportionality of a novel gabapentin formulation. The 88th Annual Meeting of the Endocrine Society; 2006:319 (abstract).
  • 171.Gordi T, Hou E, Kasichayanula S, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther. 2008;30:909–916. doi: 10.1016/j.clinthera.2008.05.008. [DOI] [PubMed] [Google Scholar]
  • 172.Sabatowski R, Gálvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26–35. doi: 10.1016/j.pain.2004.01.001. [DOI] [PubMed] [Google Scholar]
  • 173.Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain. 2009;25:185–192. doi: 10.1097/AJP.0b013e3181934276. [DOI] [PubMed] [Google Scholar]
  • 174.Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48:1378–1388. doi: 10.1177/0091270008322909. [DOI] [PubMed] [Google Scholar]
  • 175.Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72:439–446. doi: 10.1212/01.wnl.0000341770.91926.cc. [DOI] [PubMed] [Google Scholar]
  • 176.Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105:1805–1815. doi: 10.1213/01.ane.0000287643.13410.5e. [DOI] [PubMed] [Google Scholar]
  • 177.Dworkin RH, Kirkpatrick P. Pregabalin. Nat Rev Drug Discov. 2005;4:455–456. doi: 10.1038/nrd1756. [DOI] [PubMed] [Google Scholar]
  • 178.Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. Drugs. 2005;65:111–120. doi: 10.2165/00003495-200565010-00011. [DOI] [PubMed] [Google Scholar]
  • 179.Gray P. Pregabalin in the management of central neuropathic pain. Expert Opin Pharmacother. 2007;8:3035–3041. doi: 10.1517/14656566.8.17.3035. [DOI] [PubMed] [Google Scholar]
  • 180.Zareba G. Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today. 2007;41:509–516. doi: 10.1358/dot.2005.41.8.910482. [DOI] [PubMed] [Google Scholar]
  • 181.Owen RT. Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc) 2007;43:857–863. doi: 10.1358/dot.2007.43.12.1140689. [DOI] [PubMed] [Google Scholar]
  • 182.Stacey BR, Swift JN. Pregabalin for neuropathic pain based on recent clinical trials. Curr Pain Headache Rep. 2006;10:179–184. doi: 10.1007/s11916-006-0043-x. [DOI] [PubMed] [Google Scholar]
  • 183.Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273. doi: 10.1002/art.20983. [DOI] [PubMed] [Google Scholar]
  • 184.Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, Rico-Villademoros F, Hidalgo J. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry. 2007;40:68–71. doi: 10.1055/s-2007-972572. [DOI] [PubMed] [Google Scholar]
  • 185.Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–514. [PubMed] [Google Scholar]
  • 186.Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805. doi: 10.1016/j.jpain.2008.03.013. [DOI] [PubMed] [Google Scholar]
  • 187.Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419–431. doi: 10.1016/j.pain.2008.02.027. [DOI] [PubMed] [Google Scholar]
  • 188.Recla JM, Sarantopoulos CD. Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy? Med Hypotheses. 2009;73:177–189. doi: 10.1016/j.mehy.2009.01.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 189.De Lange FP, Knoop H, Bleijenberg G, Van der Meer JW, Hagoort P, Toni I. Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage. 2005;26:777–781. doi: 10.1016/j.neuroimage.2005.02.037. [DOI] [PubMed] [Google Scholar]
  • 190.Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chizh BA, Bushnell MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci. 2007;27:4004–4007. doi: 10.1523/JNEUROSCI.0098-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 191.Okada T, Tanaka M, Kuratsune H, Watanabe Y, Sadato N. Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome. BMC Neurol. 2004;4:14–14. doi: 10.1186/1471-2377-4-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 192.Schmidt-Wilcke T, Luerding R, Weigand T, et al. Striatal grey matter increase in patients suffering from fibromyalgia--a voxel-based morphometry study. Pain. 2007;132(suppl 1):S109–116. doi: 10.1016/j.pain.2007.05.010. [DOI] [PubMed] [Google Scholar]
  • 193.Schmidt-Wilcke T, Leinisch E, Straube A, et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005;65:1483–1486. doi: 10.1212/01.wnl.0000183067.94400.80. [DOI] [PubMed] [Google Scholar]
  • 194.Villarreal G, Hamilton DA, Petropoulos H, et al. Reduced hippocampal volume and total white matter volume in posttraumatic stress disorder. Biol Psychiatry. 2002;52:119–125. doi: 10.1016/s0006-3223(02)01359-8. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES